Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why ...

Morgan Stanley analyst Erin Wright maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $243.00. The ...

In the wake of the 2024 U.S. elections, stakeholders in the life sciences and health care industry are intensely focused on the policy ...

A tide change is rippling across healthcare. As industry leaders converged on San Francisco for the 2025 JP Morgan Healthcare conference, they echoed optimism about a renewed stability in healthcare, ...

Another year at the J.P. Morgan Healthcare Conference is in the books. | While major payers skipped out on this year’s event, ...

UNC Health and Duke Health formed a joint venture to build a 500-bed, free-standing children's hospital in the Piedmont, ...

Small and medium-sized enterprises are always looking for ways to run effective trials at a reasonable cost. It has become a ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...

Surgery centers are the next focus, President and CEO Martin Bonick told a recent industry conference. But that push is more ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...